Eli Lilly and Company ranks near the peer group median, with a relatively even profile across the main dimensions. Price action is lagging the structural profile — current market behavior is not yet confirming the structural position.
Peer-relative scores, weakest to strongest
Eli Lilly is a global pharmaceutical company specializing in diabetes, oncology, immunology, and neuroscience. Its recent growth has been driven by GLP-1 therapies for diabetes and obesity.
Capital efficiency (ROIC 37.76%) and sector-leading operating margins (44.9%) position Eli Lilly at the top end of pharmaceutical profitability, yet market confidence remains low with a stability score of 14/100, indicating that the premium is not fully supported by current perceptions. The company’s rapid revenue growth of 42.6% year-on-year reflects strong operational momentum, but market reluctance to assign a stable premium to these fundamentals persists.
The stability score of 14/100 reflects entrenched market risk perceptions. One-year volatility at 41.5% is significantly higher than sector averages, and a maximum drawdown of -34.5% demonstrates the extent of confidence fluctuations despite strong performance. The upcoming regulatory approval for Eli Lilly’s oral GLP-1 drug (expected Q2 2026) is a positive development, but market confidence has not yet stabilized around the company’s growth trajectory.
Recent regulatory approvals, particularly for the oral GLP-1, support the growth outlook. Eli Lilly’s manufacturing expansion in response to rising GLP-1 demand places it ahead of peers operationally. However, these factors have not yet resulted in more stable market perceptions, as volatility and risk pricing remain elevated.
Compared to peers, Eli Lilly’s combination of profitability and growth is uncommon, but the market confidence gap is more pronounced than for most direct competitors. While some peers, such as GTT.PA, also have high quality scores, few exhibit such a marked disconnect between operational strength and market stability. This gap appears partly related to Eli Lilly’s significant GLP-1 exposure and market sensitivity to execution risks.
A more stable premium would require market confidence to improve and volatility to decrease. Progress would be supported by successful execution on manufacturing expansion and regulatory milestones. Until then, Eli Lilly’s valuation reflects a quality premium under pressure.
Break down LLY's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.